Drug intelligence / Profile preview

JNJ-74856665

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ-74856665 is an orally bioavailable, potent, and selective small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), developed by Janssen Research & Development for the treatment of hematologic malignancies. By binding to the ubiquinone binding site of DHODH, it inhibits this enzyme in the pyrimidine biosynthesis pathway, leading to cell cycle arrest and apoptosis as well as promoting differentiation in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The drug is currently being evaluated in Phase 1 clinical trials as monotherapy or in combination with azacitidine or venetoclax for AML, MDS, and chronic myelomonocytic leukemia (CMML)[1][2][3][5][7].

Targets

DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)

Beyond the preview

Go deeper on JNJ-74856665.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-74856665.

Explore the full profile